ArticleAIDS and behavior2026
Patient-Reported Outcomes Among Virally Suppressed People Living with HIV Switching to Dolutegravir/Lamivudine vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide from the Randomized DYAD Study.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In the DYAD study, switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults. Here, we present changes in patient-reported outcomes (PROs) among participants who completed Week (W) 48. DYAD used PRO measures to evaluate HIV- and antiretroviral-related symptoms (HIV-SI) and treatment satisfaction (HIVTSQ/c) at baseline, W24, and W48. Symptoms described as bothersome versus not bothersome were compared across time by treatment group using chi-squared testing. Changes from baseline in HIV-SI and HIVTSQ/c scores were compared between treatment groups using adjusted ANCOVA models. Overall, 134 on DTG/3TC and 65 on B/F/TAF completed W48. At W24, 16% on DTG/3TC reported headache as bothersome versus 6% on B/F/TAF (p = 0.04); however, at W48, there was no significant difference in headache. At W48, 10% on DTG/3TC reported diarrhea as bothersome versus 0% on B/F/TAF (p = 0.01); however, there was no significant difference in diarrhea at W24. There were no other significant differences in bothersome symptoms through W48. At W48, both DTG/3TC and B/F/TAF participants demonstrated small, nonsignificantly different reductions in HIV-SI symptom score (-5.9 versus -4.3; adjusted treatment difference, -1.6; 95% confidence interval [CI]: -4.8, 1.5) and treatment satisfaction score (-3.7 versus -3.2; adjusted treatment difference, -0.5; 95% CI: -6.5, 5.5). In DYAD, both DTG/3TC and B/F/TAF were associated with similar, small reductions in overall symptom burden and stable treatment satisfaction scores at W48. These data support DTG/3TC as a switch option with comparable symptom burden and treatment satisfaction to modern 3-drug integrase inhibitor-based regimens.
Indexed as
Identifiers
42809088What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.